Safety and efficacy of OVV-01 injection for advanced solid tumors
Part of Cancer clinical trials.
This study tests a new cancer treatment called OVV-01 that is injected directly into tumors or given through the vein. It's for patients with advanced solid cancers (like melanoma, lung, breast, or colon cancer) who have already tried at least two standard treatments without success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Advanced solid tumor (melanoma, head/neck, breast, lung, colon, liver, stomach, bone sarcoma, cervical, or nasopharyngeal cancer) that cannot be surgically removed or has spread
- Failed at least two standard cancer treatments (like chemotherapy, immunotherapy, or targeted drugs)
- At least one measurable tumor visible on imaging that is large enough to inject (some tumors must be over 1 cm)
- Good overall health (ECOG score 0–1) with expected survival of at least 12 weeks and normal blood counts and organ function
- No brain cancer spread, recent radiotherapy to the tumor, or serious heart, infection, or autoimmune conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental therapy that combines a new drug (OVV-01) given intravenously and injected directly into tumors, along with another immunotherapy drug (AK112). It's for people with advanced solid tumors who have run out of standard options, and it aims to see if the combination can shrink tumors or slow their growth.
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
This study tests a new combination treatment: a modified virus (hV01) injected directly into a tumor, plus a drug that helps your immune system attack cancer cells (PD-1 inhibitor). It is for people with advanced solid tumors that have not responded to standard therapies.
This trial tests two new injectable drugs for advanced solid tumors, especially kidney, head and neck, cervical, and ovarian cancers. The goal is to see if the combination is safe and if it can shrink tumors.
This trial tests an investigational cell therapy, IOV-5001, in adults with certain advanced cancers (lung, breast, colorectal, or head and neck). The therapy uses a patient's own immune cells to target the tumor, and the study aims to see if it can slow or stop cancer growth.
This Phase 1 study tests BAT8008 injection to see how safe it is, how well the body handles it, and how it affects the body’s drug levels. It’s for adults with advanced or metastatic solid tumors that are not responding to, or can’t be tolerated with, standard treatments.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.